BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251104
DTEND;VALUE=DATE:20251107
DTSTAMP:20260515T025739
CREATED:20250627T101712Z
LAST-MODIFIED:20250627T101712Z
UID:41418-1762214400-1762473599@www.pharmajournalist.com
SUMMARY:2nd Patient Recruitment in Rare Disease Trials
DESCRIPTION:The rare disease trial landscape stands at a pivotal tipping point. While unprecedented advances in trial design\, digital tools\, and regulatory flexibility are accelerating innovation like never before\, the reality for patients remains stark: over 90% of rare diseases still lack an FDA-approved treatment. For many\, clinical trials represent the only path to care\, yet access remains uneven. Geographic isolation\, diagnostic delays\, and socioeconomic barriers continue to exclude many patients\, especially from underserved communities\, from participating in research. \nAdd to this the small\, dispersed patient populations\, high protocol complexity\, and a shortage of disease-specific expertise\, and it’s clear that traditional recruitment approaches no longer suffice. \nNow in its second year\, the Patient Recruitment for Rare Disease Trials Summit stands as the premier forum dedicated to closing this critical gap. Designed for leaders in Patient Recruitment\, Clinical Operations\, Patient Advocacy\, and Medical Affairs this summit unites innovators reshaping rare disease trial access across the entire patient journey. Over three focused days in Boston\, you’ll explore cutting-edge strategies spanning early patient identification to decentralized\, patient-centric trial models that support participants from diagnosis through to long-term retention. Now is the time to accelerate creative recruitment strategies\, deepen early patient engagement\, and harness innovative technologies to ensure no rare disease patient is left behind in the race for transformative therapies. \nYou’ll join 70+ leaders from companies like Biogen\, Takeda\, Teva Pharmaceuticals\, Genentech\, Tenaya Therapeutics\, and Sarepta Therapeutics\, sharing what’s worked – and what hasn’t – when it comes to recruiting\, retaining\, and supporting rare disease patients through clinical trials. \nWhether you’re running a trial for a rare neurological disorder\, launching a global gene therapy study\, or building support programs around ultra-small populations\, the 2nd Patient Recruitment for Rare Disease Trials Summit is your strategic launchpad. \nTo know more visit: https://ter.li/qxs28b
URL:http://www.pharmajournalist.com/event/2nd-patient-recruitment-in-rare-disease-trials/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251104
DTEND;VALUE=DATE:20251107
DTSTAMP:20260515T025739
CREATED:20250916T110442Z
LAST-MODIFIED:20250916T110506Z
UID:41950-1762214400-1762473599@www.pharmajournalist.com
SUMMARY:LEAP HR: Emerging Biopharma
DESCRIPTION:Funding pressures\, regulatory shifts\, global competition\, and relentless layoffs are redefining the pre-commercial biopharma landscape. In this climate\, agile\, transparent\, and people-first leadership is critical to keeping teams engaged\, culture strong\, and organizations moving forward. \nLEAP HR: Emerging Biopharma is the only meeting built for senior HR leaders in this space. Over three days in Boston this November\, you’ll join peers who understand your challenges\, share proven solutions\, and offer the community support you need to navigate disruption\, adapt with resilience\, and do more with less. \nLeave equipped with fresh strategies to strengthen culture\, re-energize your workforce\, and lead through uncertainty with clarity\, community\, and confidence — ready to take on 2026 and beyond. \nLEAP HR: Emerging Biopharma is a high-energy\, high impact\, fully immersive experience. We like to keep things short\, snappy … and dare we say\, fun? Welcome to a new era of conferences – one defined by case-study driven presentations\, an ultra-niche HR life science community and our unique format\, you will never need to attend any other conference. \nLearn more: https://ter.li/o0nb7o
URL:http://www.pharmajournalist.com/event/leap-hr-emerging-biopharma-2025/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251109
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T025739
CREATED:20250613T091742Z
LAST-MODIFIED:20250613T091907Z
UID:41257-1762646400-1762905599@www.pharmajournalist.com
SUMMARY:8th Neuropsychiatric Drug Development Summit
DESCRIPTION:Industry’s Flagship Forum Capturing Advancements Across Discovery\, Preclinical\, Translational\, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics \nUniting 150+ discovery\, preclinical\, translational\, clinical\, and regulatory leaders\, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications. \n \nRecognized by key leaders as the “ideal size”\, offering a “targeted audience” perfect for meaningful networking and collaboration\, join thought leaders from Bristol Myers Squibb\, AbbVie\, Otsuka\, Johnson & Johnson\, Biogen\, Lundbeck\, Delix Therapeutics\, Boehringer Ingelheim\, and many more this September to revitalize the mental health drug development landscape. \nOver the 3 day agenda\, you’ll engage in deep-dive interactive workshops\, roundtable discussions\, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics. \nOur attendees span discovery\, in vivo pharmacology\, translational medicine\, clinical development\, medical\, regulatory affairs\, academics\, venture capitalists\, and solution providers\, ensuring that whatever part you play in transforming the mental health treatment and therapeutic landscape\, you are surrounded by peers with the knowledge and capacity to support you. \nWhen you join the Neuropsychiatric Drug Development Summit you can expect to: \n\nDecipher the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers\nDiscover innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically\nInvestigate the efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy\, and explore groundbreaking progress in novel non-hallucinogenic neuroplastogens\nReview the latest advancements in new targets and mechanisms\, including moving beyond atypical antidepressants and antipsychotics\, to truly transform patient burdens\n\nPlus\, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development\, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape. \nSo\, what are you waiting for? Learn more about the summit today and explore the 40+ leading experts presenting at this year’s meeting\, the array of sessions and bespoke workshops designed to support you\, and the companies attending to advance neuropsychiatric therapeutics. \nView the brochure now for all this and more: https://ter.li/g4f9aj
URL:http://www.pharmajournalist.com/event/8th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T025739
CREATED:20250610T104455Z
LAST-MODIFIED:20250610T111651Z
UID:41230-1762732800-1762905599@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:Have you considered how microneedle drug delivery systems could revolutionise the future of vaccine and drug administration? \nThis November\, join SAE Media’s 4th Annual Transdermal and Microneedle Drug Delivery Conference. Engage with leading drug development and delivery experts in a dynamic\, expert-led environment. Connect with forward-thinking innovators to explore cutting-edge case studies\, breakthrough vaccine and therapeutic applications\, and the evolving capabilities of transdermal and microneedle technologies. Transdermal and microneedle patches hold the potential to ‘go beyond the needle’ and transform pharmaceutical development—offering enhanced accessibility and long-term delivery solutions. With applications ranging from improved vaccine distribution to advanced diagnostics\, these technologies are poised to reshape healthcare by increasing efficacy and expanding global access to life-changing treatments. \nTo know more click here.
URL:http://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery-2025/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251113
DTSTAMP:20260515T025739
CREATED:20250703T134927Z
LAST-MODIFIED:20250703T134927Z
UID:41451-1762732800-1762991999@www.pharmajournalist.com
SUMMARY:7th Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:7th Targeted Radiopharmaceuticals Summit Europe \n10–12 November 2025 | Amsterdam \nTranslating Novel Radiopharmaceutical Therapies to Transform the Medical Future \n \nNow in its seventh year\, the Targeted Radiopharmaceuticals Summit Europe returns to Amsterdam to bring together over 200 leaders in radiopharmaceutical therapy development. Designed to establish radiopharmaceuticals as a core pillar of oncology\, this event is essential for professionals working across discovery\, clinical development\, and manufacturing. \nHighlights of the 2025 Program: \nMore than 45 expert speakers from leading companies including Bayer\, AstraZeneca\, Novartis\, Telix Pharmaceuticals\, and more\nIntroduction of a third content track\, covering:\nDiscovery & Preclinical\nTranslational & Clinical\nCMC & Sourcing\nSix in-depth workshops on key challenges including radiopharmaceutical design\, dosimetry translation\, and isotope supply \nKey Speakers: \nThomas Birger Eden-Jensen\, Head\, External Supply Management TRP\, Bayer\nMark Fielding\, Director\, CMC\, Regulatory Affairs\, TRP\, AstraZeneca NEW SPEAKER\nIsabel Jaco\, Group Leader\, RLT Drug Discovery\, Novartis NEW SPEAKER\nSandra Uhlenbroich\, Director\, Discovery\, Bicycle Therapeutics NEW SPEAKER\nFrederic Fantino\, Global Medical Affairs EMEA\, Telix Pharmaceuticals NEW SPEAKER\nThijs Spoor\, Chief Executive Officer\, Perspective Therapeutics NEW SPEAKER\nSigal Kalmanson\, Chief Executive Officer\, Starget Pharma \nTopics Include: \nNovel target discovery\, including SSTR3 and FAP\nIsotope selection and supply chain resilience\nTranslating dosimetry into clinical studies\nFirst-in-human study design and Phase 0 considerations\nScalable and compliant manufacturing strategies \nThis is the most comprehensive European agenda for targeted radiopharmaceuticals to date\, built to accelerate asset development and address the sector’s most pressing challenges. \nView the full program: https://ter.li/gowcuf \nHyperlink – https://ter.li/gowcuf
URL:http://www.pharmajournalist.com/event/7th-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Mövenpick Hotel Amsterdam City Centre\, Piet Heinkade 11\, Amsterdam\, 1019 BR\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251111
DTEND;VALUE=DATE:20251114
DTSTAMP:20260515T025739
CREATED:20250829T114659Z
LAST-MODIFIED:20250829T114659Z
UID:41812-1762819200-1763078399@www.pharmajournalist.com
SUMMARY:7th TIL Therapies Summit
DESCRIPTION:Now in its seventh year\, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13\, 2025\, in Boston (MA)\, this summit unites global experts across biopharma\, academia\, clinical practice\, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments. \nFollowing the first-ever FDA approval of a TIL therapy in the U.S.\, and with regulatory decisions pending in Canada and Europe\, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection\, engineering\, and manufacturing can unlock scalable\, potent treatments for solid tumors beyond melanoma. \nThe program is designed to tackle the most pressing challenges in TIL development\, including: \n\nEngineering TILs for improved persistence\, potency\, and specificity\nManufacturing innovations in closed systems to speed-up turnaround\, and reduce IL-2 dependency\nClinical trial design and patient access strategies\nBiomarker discovery and potency assay development\nReal-world implementation and patient/provider perspectives\n\nWith 28+ expert speakers\, 50+ attendees\, and 8 hours of dedicated networking\, the summit fosters a collaborative environment for sharing cutting-edge science\, operational insights\, and lived experiences. Attendees will hear from leading voices including: \n\nInge Jedema\, Netherlands Cancer Institute\nJingwei Sun\, Grit Biotechnology\nMadan Jagasia\, Obsidian Therapeutics\nMicah Benson\, KSQ Therapeutics\nMichael Lotze\, University of Pittsburgh\nRoda Amaria\, MD Anderson Cancer Center\n\nYou can see who else is speaking in this year’s program: https://ter.li/i4a730 \nWhether you’re preparing for your first clinical trial\, scaling manufacturing\, or navigating regulatory pathways\, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value. \nUnlike broader cell therapy events\, the TIL Therapies Summit offers a focused\, intimate setting where attendees can engage in meaningful dialogue\, build lasting partnerships\, and stay ahead of the curve in this rapidly evolving space. \nIf you’re committed to transforming the treatment landscape for solid tumors\, the 7th TIL Therapies Summit is your must-attend event for 2025. \nFind out more here: https://ter.li/nfdnks
URL:http://www.pharmajournalist.com/event/7th-til-therapies-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251117
DTEND;VALUE=DATE:20251120
DTSTAMP:20260515T025739
CREATED:20250905T113422Z
LAST-MODIFIED:20250905T113422Z
UID:41887-1763337600-1763596799@www.pharmajournalist.com
SUMMARY:9th Antifibrotic Drug Development Summit
DESCRIPTION:2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s\, Boehringer’s Phase 3 IPF data\, Stanford’s TGF-β work in cardiovascular fibrosis\, to over $3B in deals from Lilly\, GSK\, and others\, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. \nThat’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November.  Learn from the industry’s premier experts at the forefront of fibrosis research\, gain unmissable cross-fibrosis insights\, and make unmatched connections with 80+ industry leaders from Pfizer\, Eli Lilly\, Novartis\, Takeda and more! \nAccess this year’s incredible lineup of speakers \nJoin us this year to: \n\nUnlock novel targets with advances in single-cell and spatial omics\, immune-stromal interactions\, and cross-tissue mechanisms\, featuring insights from Harvard Medical School\, Gilead Sciences\, and AdaptVac\nStrengthen translational confidence with precision-cut tissue slices\, 3D models\, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success\nDesign winning clinical programs with lessons from recent Phase 2 data\, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma\nNavigate the evolving landscape with expert perspectives on combination therapies\, GLP-1 competition\, and investor priorities to position your pipeline for partnerships and approvals\n\nDon’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings! \nSecure my spot
URL:http://www.pharmajournalist.com/event/9th-antifibrotic-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025739
CREATED:20250731T102550Z
LAST-MODIFIED:20250731T102550Z
UID:41600-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:Model-Informed Drug Development Summit
DESCRIPTION:With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing\, regulatory change is accelerating\, solidifying Model-Informed Drug Development (MIDD) as a critical\, non-negotiable tool in the drug development process. \nThe Model-Informed Drug Development Summit is the first and only industry-focused\, 3-day strategic meeting dedicated to exploring how MIDD is transforming decision-making and driving drug development success. This is your opportunity to benchmark against industry leaders\, refine your strategy\, and future-proof your development approach. \nJoin senior experts in pharmacometrics\, clinical pharmacology\, PK/PD\, and modeling from leading organizations including Pfizer\, Third Rock Ventures\, Johnson & Johnson\, AbbVie\, and more\, as they uncover how MIDD is being used to: \n\nSelect better candidates earlier in development\nStreamline or eliminate clinical trial phases\nPersonalize and optimize trial designs\nBuild stronger\, data-driven regulatory submissions\n\nWhy Attend? \n\nUnlock real-world case studies showing how MIDD accelerates timelines\, cuts costs\, and improves outcomes\nGain insight into how peers are implementing MIDD from discovery through to regulatory approval\nCollaborate with cross-functional teams to exchange strategies and overcome shared challenges\n\nWith exclusive insights into ICH M15\, practical applications across diverse therapeutic areas\, and proven examples of success\, this summit is your one-stop shop for unleashing the full potential of MIDD. \nLearn more here: https://ter.li/unljt8
URL:http://www.pharmajournalist.com/event/model-informed-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025739
CREATED:20250731T103150Z
LAST-MODIFIED:20250731T103150Z
UID:41605-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:3rd LNP Characterization & Analytical Development Summit
DESCRIPTION:3rd LNP Characterization & Analytical Development Summit\nDe-Risk Regulatory Submissions Through Smarter LNP Characterization \nCurated in collaboration with leading analytical scientists and key LNP stakeholders\, the 3rd LNP Characterization & Analytical Development Summit returns with new data\, fresh insights\, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization\, this summit is your go-to platform for driving the development of safe\, effective\, and high-quality LNP-based drug products. \nThis highly focused\, three-day agenda will equip analytical experts with the technical insights needed to: \n\nAccelerate development timelines\nBridge critical analytical gaps\nStreamline regulatory submissions for faster approval\n\nJoin over 90 industry leaders in analytics\, characterization\, assays\, and CMC from organizations including Pfizer\, Novo Nordisk\, Prime Medicine\, Tessera Therapeutics\, GSK\, Sanofi\, and more. \nKey Benefits of Attending: \n\nGain deep technical knowledge on cutting-edge LNP analytics\nDiscover strategies to overcome common characterization challenges\nAlign on regulatory expectations to support faster\, smoother submissions\nNetwork with peers tackling the same development and regulatory hurdles\n\nWith data-driven presentations and expert-led discussions\, this is your opportunity to help define and implement robust analytical strategies that support the rapid development and approval of next-generation genomic medicines. \nLearn more here: https://ter.li/ympfix
URL:http://www.pharmajournalist.com/event/3rd-lnp-characterization-analytical-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025739
CREATED:20250829T120700Z
LAST-MODIFIED:20250829T120700Z
UID:41824-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:7th Myeloid-Directed Therapies Summit
DESCRIPTION:The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology\, Inflammation and Beyond… \nUniting leading experts from pharma\, biotech\, and academia\, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells\, this forum dives into myeloid reprogramming\, cell state heterogeneity\, and translational challenges to unlock next-generation immune modulation. \nWith breakthrough insights from Eli Lilly\, AbbVie\, Pfizer\, AstraZeneca\, and Faron Pharmaceuticals\, and cutting-edge academic labs\, this is your opportunity to explore clinical case studies\, dissect failed monotherapy lessons\, and gain clarity on patient stratification\, trial design\, and combination strategies. \nLearn more: https://ter.li/by8e82
URL:http://www.pharmajournalist.com/event/7th-myeloid-directed-therapies-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025739
CREATED:20250912T125210Z
LAST-MODIFIED:20250912T130631Z
UID:41941-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:9th Dermatology Drug Development Summit
DESCRIPTION:The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research\, and clinical pipelines facing intensifying competition\, the need to develop differentiated\, novel candidates has never been more critical. \nAs the field accelerates with clinical and commercial momentum\, highlighted by Sanofi’s continued success with Dupixent\, Corvus’ promising Phase 1 data on Soquelitinib\, and landmark deals such as Gilead’s $1.7B inflammation partnership with LEO Pharma – this summit provides an essential platform to stay ahead of the curve. Returning this November\, the meeting unites 120+ leading experts from pharma\, biotech\, and academia\, all dedicated to overcoming the most pressing R&D bottlenecks in dermatology drug development. \nAttendees will gain insights into the latest preclinical and clinical findings across both rare and common conditions\, including atopic dermatitis\, psoriasis\, hidradenitis suppurativa\, vitiligo\, pemphigus nodularis\, bullous pemphigoid\, and alopecia areata. Sessions will explore the complexity of disease heterogeneity\, emerging mechanisms of action\, safety considerations\, and the evolving regulatory landscape. With contributions from thought leaders at AbbVie\, Sanofi\, Takeda\, Incyte\, Merck\, and other trailblazing organizations\, discussions will span discovery\, preclinical\, translational\, clinical\, and medical affairs perspectives. \nThe program also offers a forward-looking exploration of the modalities reshaping dermatology pipelines\, from bispecifics and biologics to oligonucleotides and beyond. By combining cutting-edge science with real-world clinical and strategic insights\, the 9th Dermatology Drug Development Summit equips participants with the tools to accelerate innovation\, navigate increasing competition\, and ultimately deliver therapies that transform patient quality of life. \nIf you’d like to learn more about the summit\, download the event guide or get in touch!
URL:http://www.pharmajournalist.com/event/9th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T025739
CREATED:20250829T114330Z
LAST-MODIFIED:20250829T114330Z
UID:41806-1763510400-1763683199@www.pharmajournalist.com
SUMMARY:3rd Donor Selection & Cell Source Summit
DESCRIPTION:Returning for its third year\, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell sourcing for allogeneic therapies. \nThis summit brings together leading minds from biopharma\, blood banks\, apheresis providers\, and cell therapy innovators to address one of the most critical bottlenecks in the development of scalable\, off-the-shelf treatments. \nWith over 600 allogeneic clinical trials currently underway\, the pressure to secure high-quality\, consistent donor-derived starting material has never been greater. This summit provides a unique opportunity to explore how smarter donor screening\, recruitment\, and retention strategies can directly impact product quality\, manufacturing scalability\, and clinical success. \nAttendees will gain actionable insights into: \n\nDonor testing and screening protocols that improve product safety and consistency\nRetention strategies to build reliable donor pools\nCryobiology and supply chain innovations that enhance cell viability and streamline logistics\nAnalytical development and quality control for robust characterization of starting material\n\nSee what other insights you can walk-away with in the program: https://ter.li/c2h7ym \nThe summit features expert speakers from leading organizations including Bristol Myers Squibb\, Genentech\, Allogene Therapeutics\, ImmuneBridge\, NKILT\, Luminary Therapeutics\, and many more offering a cross-functional perspective on how donor and source decisions shape the future of cell therapy. \nUnlike broader cell therapy conferences\, this event zeroes in on the upstream decisions that define downstream success. Whether you’re optimizing donor engagement\, navigating regulatory complexities\, or refining your sourcing strategy\, the Donor Selection & Cell Source Summit provides the tools and connections to move your program forward. \nExpect two days of deep scientific exchange\, strategic discussion\, and collaborative problem-solving in an intimate setting designed to foster meaningful dialogue. If you’re working to unlock the full potential of allogeneic therapies\, this is the one event you can’t afford to miss. \nFor more information on the summit\, view the program: https://ter.li/dc18d1
URL:http://www.pharmajournalist.com/event/3rd-donor-selection-cell-source-summit/
LOCATION:Westin Bayview San Diego\, 1051 Columbia St\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR